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ABSTRACT. The enantioselective catalytic hydrogenation of N-(3,4-dihydronaphthalen-2-yl) amides 
(1) with rhodium catalysts bearing phosphine-phosphite ligands 4 has been studied. A wide catalyst 
screening, facilitated by the modular structure of 4, has found a highly enantioselective catalyst for this 
reaction. This catalyst gives a 93 % ee in the hydrogenation of 1a and also produces high 
enantioselectivities, ranging from 83 to 93 % ee, in the hydrogenation of several –OMe and –Br 
substituted substrates. On the contrary, structurally related enol esters 2 are very reluctant to the 
hydrogenation. A coordination study of representative enamide 1d has shown an unusual η6-arene 
coordination mode, over the typical O,C,C chelating mode for enamides, as the preferred one for this 
substrate in a Rh(I) complex. Deuteration reactions of 1c and 1d indicate a clean syn addition of 
deuterium to the double bond without isotopic effect on enantioselectivity. 
 
 
Introduction 
 
Chiral 2-aminotetralines comprise an important class of compounds in medicinal chemistry.1 
Comprehensive information covering the biological properties of a large number of examples can be 
found in the literature and remarkably, several examples have found application in the pharmaceutical 
industry (Figure 1).2 Due to the importance of these chiral derivatives, the development of efficient 
procedures for the synthesis of a broad range of these amines is highly desirable. As N-(3,4-
dihydronaphthalen-2-yl) amides can readily be prepared in one step from commercially available 2-
tetralones,3 the hydrogenation of these enamides provides a straightforward procedure for the 
preparation of chiral 2-aminotetraline derivatives. 
 3
Diverse catalysts,4-6 mostly based on ruthenium and rhodium complexes, have been examined in the 
hydrogenation of the aforementioned enamides with very dissimilar performance. Thus, ruthenium 
catalysts with diphosphine ligands have provided good activity and enantioselectivity levels, in the 
hydrogenation of several examples under relatively high hydrogen pressures (20-100 atm).1a, 4 In 
contrast to that, rhodium catalysts usually show higher activity but they have consistently given low 
enantioselectivities in the hydrogenation of the representative substrate N-(3,4-dihydronaphthalen-2-yl) 
acetamide (A, Figure 2).5 This is a rather surprising aspect considering that compound A possess the 
auxiliary amide carbonyl group needed for substrate chelation,7 and the vast range of Rh catalysts tested 
in the hydrogenation of this substrate. 
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Figure 1. Chiral aminotetralines with pharmaceutical application. 
 
A notable exception among the rhodium catalysts described has been provided by a supramolecular 
complex containing phosphine and phosphite ligands, named Supraphos, described by the group of 
Reek.8 Following an approach based on the generation of chelating ligands from monodentate 
assembling ones, these researchers have achieved a catalyst which provides an outstanding 94 % ee in 
the hydrogenation of N-(3,4-dihydronaphthalen-2-yl) acetamide. 
 4
A comparison between compound A and types of enamides which typically provide highly 
enantioselective hydrogenations with Rh catalysts, like dehydroaminoacids (B), enamido phosphonates 
(C) or aryl enamides (D),9 reveals some important differences. First of all, compounds B, C, and to a 
lesser extent D, possess an electron-withdrawing group bonded to the same carbon (α) as the amido 
group. This arrangement favours the regioselectivity of the olefin insertion step to give an α-alkyl 
intermediate F. On the contrary, the substitution of the accepting group by an alkyl group and the 
presence of a β-aryl group may favour the formation of a β-alkyl intermediate G in the hydrogenation of 
substrates A.10 Moreover, several studies have connected a change in the regioselectivity of the olefin 
insertion step with a product enantioreversal.10a, 11 Thus, if a competition between α- and β-alkyl 
pathways occurs, a severe drop in enantioselectivity may also take place. Moreover, the cyclic nature of 
enamides A, which imposes an E olefin configuration, probably impedes achieving high 
enantioselectivities. At this regard, it should be mentioned that Zhang and coworkers have recently 
demonstrated that the hydrogenation of E isomers of acyclic enamides E occurs with significantly lower 
enantioselectivity than that of Z isomers.12 Likewise, E-α-acetamidocinnamic acid derivatives usually 
give less enantioselective hydrogenations than isomers Z (B).13 
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Figure 2. Structures A-G. 
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In recent years, we have studied the application of chiral phosphine-phosphites in the hydrogenation of 
several types of olefins by Rh catalysts.11c, 14 From this background and inspired by the results reported 
for the Supraphos catalysts, we were interested to investigate the performance of rhodium complexes 
based on the conventional phosphine-phosphites developed in our laboratory, in the hydrogenation of 
the challenging enamide A. Herein, we describe an extensive catalyst screening using a family of 
phosphine-phosphite ligands in the hydrogenation of several N-(3,4-dihydronaphthalen-2-yl) amides. 
Following a systematic optimization procedure, a highly enantioselective catalyst for this kind of 
substrates has been found. 
 
 
Results and Discussion 
 
Synthesis of substrates. A series of N-(3,4-dihydronaphthalen-2-yl) amides 1 has been prepared by 
condensation between commercially available 2-tetralones and acetamide or benzamide in the presence 
of a catalytic amount of acid in moderate yields (Scheme 1).3 In the set, several methoxy substituted 
examples have been considered, as they can provide a convenient access to important hydroxy-2-
aminotetralines.15 Likewise, structurally similar enol esters 2 were prepared from 2-tetralone using 
literature procedures.16 For comparative purposes, enamide 3 derived from α-tetralone was also 
included. 
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Scheme 1. Synthesis and structures of investigated olefin substrates. 
 
Influence of the ligand in the asymmetric hydrogenation. The hydrogenation of the representative 
enamide 1a with Rh catalyst precursors based on phosphine-phosphite ligands 4 (Scheme 2, Chart 1), 
using either isolated catalyst precursors of formulation [Rh(COD)(4)]BF4 (5),14 or generated in situ from 
[Rh(COD)2]BF4 and an stoichiometric amount of 4, has been investigated. The library of chiral ligands 
contains examples which mainly differ in the nature of the backbone: benzene (4a), ethane (4b-4d) or 
substituted ethane (4e-4k). Moreover, the ligands in the set differ in the position of the stereogenic 
elements. Thus, ligands 4l and 4m possess a P-stereogenic phosphino fragment. On the other hand, 
ligands 4e-4h contain a stereogenic center at the β-position (to the phosphine) of the backbone, while 
for ligands 4j and 4k the stereogenic center is at position α. In addition, all of the examples contain an 
atropisomeric phosphite fragment. 
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Scheme 2. Hydrogenation reaction of enamides 1. 
 
In an initial approach, we examined precatalysts 5a and 5b in the reduction of 1a at 20 bar of 
hydrogen and room temperature, as low conversions at 4 bar of hydrogen were observed. Among them, 
catalyst based on less rigid 4b offered a superior activity and enantioselectivity (entries 1 and 2, Table 
1). An attempt to increase conversion by using alternative phosphine fragments proved to be fruitless 
(entries 3,4). After these preliminary results, we performed a set of reactions under different initial 
hydrogen pressures (entries 5-6), without improvement over the value obtained at 20 atm. In addition, an 
increase in temperature up to 40 ºC had a deleterious effect on enantioselectivity (entry 7). 
On the other hand, considering that the Rh-Supraphos catalytic system is capable to provide high 
enantioselectivities in the presence of a considerable amount of diisopropylethylamine (DIPEA) as an 
additive,8, 17 the hydrogenation of 1a with catalyst precursors 5a, 5b and 5d in the presence of 20 
equivalents of DIPEA was examined. Most notably, the base has a critical influence on the present 
catalytic system. It produces an important, particularly for catalyst based on 4a, increase in conversion, 
although racemic products were unexpectedly obtained (entries 8-10).18-19 It is noteworthy that catalysts 
with different phosphine groups and dynamic properties give null enantioselectivity, pointing to a 
general effect of the additive. It looks therefore apparent that the addition of base leads to an alternative 
catalyst. In connection with this it should be mentioned that the deprotonation of cationic dihydrides to 
give neutral monohydrides, which are highly active olefin hydrogenation catalysts, has been well 
documented in the literature.20 Comparing with diphosphine catalysts, the presence of the pi-acceptor 
phosphite group in P-OP ligand should increase the acidity of corresponding cationic dihydrides, 
favouring deprotonation by the amine. However, the complexity of the system does not confidently 
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allow us to assign the lack of enantioselectivity to the purported monohydride Rh(H)(P-OP)(S)n (S = 
solvent, n = 1-3) over other alternatives like the formation of metallic clusters upon addition of base,21 
the dissociation or the decomposition of the chiral ligand. Therefore, a specific study covering 
alternative ligands, additives and substrates is needed to clarify this effect. 
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Chart 1. Phosphine-phosphite ligands 4 used in this study. 
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Finally, from a practical point of view, it is interesting to note that similar results were obtained with 
5b and the catalyst generated in situ from [Rh(COD)2]BF4 and 1.1 equivalents of 4b (entry 1, Table 2). 
Thus, the analysis of the influence of the ligand was performed with catalyst precursors generated in 
situ. 
After the result shown by the ethane bridged complex 5b, we tried to improve catalyst 
enantioselectivity by tuning the backbone structure with substituents in either α or β positions with a 
defined stereochemistry.14d Pairs of ligands with β-Ph (4e, 4f) and β-Me (4g, 4h) substituents, with 
different relative backbone configuration to the biphenyl phosphite fragment, as well as β-Me2 example 
(4i) were then tested (entries 2-6). No improvement over the result obtained with 4b was obtained, 
therefore concluding that the presence of the β substituent is detrimental in these reactions. In contrast, 
catalysts with an α-Me group to the phosphine group provided relatively good enantioselectivity values 
of 75 % ee (4j, entry 7) and 81 % ee (4k, entry 8). The latter catalyst is only slightly more 
enantioselective than catalyst based on 4b, and the small improvement does not justify the introduction 
of an additional stereogenic center. Overall, the most simple ethane backbone looks more suitable for 
this reaction. However, the latter results offered a hint for a further enhancement of the catalyst. The 
presence of the α-methyl group in ligands 4j and 4k favours a chiral distribution of aryl phosphine 
substituents,22 and prompted us to investigate examples with a P-stereogenic biarylphosphino fragment. 
Thus, diastereomeric ligands 4l and 4m bearing a P(o-An)Ph group were examined.14d Most noteworthy, 
catalyst based on ligand 4l produced a significant improvement on enantioselectivity up to 93 % ee 
(entry 9). On the other hand, the catalyst bearing ligand 4m gave lower enantioselectivity (77 % ee, entry 
10). A comparison between these results indicates that the configuration of the product is determined by 
the configuration of the phosphite, as observed before in the hydrogenation of methyl Z-(α)-N-
acetamido cinnamate (MAC) and other olefins.14 It should also be mentioned that the enantioselectivity 
provided by catalyst based on 4l is very close to the best value obtained with a Rh catalyst in this 
reaction (94 % ee).8 
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Table 1. Hydrogenation of 1a using complexes [Rh(COD)(4)]BF4a 
Entry P-OP ligand P (atm H2) % conv % ee (conf) 
1 4a 20 18 68 (S) 
2 4b 20 63 81 (S) 
3b 4c 20 15 46 (S) 
4 4d 20 67 38 (S) 
5 4b 10 50 63 (S) 
6 4b 30 64 77 (S) 
7c 4b 30 92 53 (S) 
8d 4a 20 100 rac 
9d 4b 20 100 rac 
10d 4d 20 100 rac 
aReactions were carried out in CH2Cl2 at room temperature unless otherwise specified. S/C = 100, 
reaction time 21 h. Conversion was determined by 1H NMR and enantiomeric excess by Chiral GC. 
Configuration was determined by comparing the sign of optical rotation with literature data.5d 
bPrecatalyst prepared in situ from [Rh(COD)2]BF4 and 1.1 equivalents of 4c. cReaction performed at 40 
ºC. dReactions performed in the presence of 20 equiv of DIPEA. 
 
Scope of the reaction. We further investigated the scope of catalyst bearing 4l in the reduction of 
enamides 1 (Table 3). Most noteworthy relatively high enantioselectivities, between 83 and 93 % ee, 
were observed in these reactions. Thus, benzamide 1b gave a 93 % ee, although it was less reactive than 
1a, and produced a moderate conversion (entry 1). An increase in the temperature to 40 ºC raised 
conversion to 70 %, but the enantioselectivity decreased to 82 % ee (entry 2). Alternatively, catalyst 
bearing ligand 4k produced lower levels of conversion and enantioselectivity (entry 3). Methoxy 
substituted substrates 1c and 1d provided good conversions with enantioselectivities of 88 and 86 % ee 
(entries 4-5), respectively. Most interestingly, substrate 1e, which should apparently be more 
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encumbered than the latter enamides, is significantly more reactive. Thus, catalysts bearing ligands 4a, 
4m and 4l gave full conversions for this substrate (entries 6-8). Among the catalysts investigated, that 
based on 4l produced again the best enantioselectivity (93 % ee). Moreover, bromide 1f showed a lower 
reactivity under our standard conditions, giving a conversion of 67 % and 83 % ee (entry 9). The 
reaction at 40 ºC showed a slightly higher conversion (70 %) and a lower enantioselectivity (80 % ee, 
entry 10). Alternatively, diastereomeric catalyst based on ligand 4m, showed a better conversion and a 
lower enantioselectivity than catalyst of 4l (entry 11). A perusal of the literature indicates that 
hydrogenation of substrates 1c, 1e and 1f have not been reported before, while catalyst of 4l provides the 
highest enantioselectivity among Rh complexes in the hydrogenation of 1b and 1d. For the latter 
substrates, the best enantioselectivities, 96 and 95 % ee respectively, have been provided by Ru 
complexes.4c, 4e 
 
Table 2. Hydrogenation of 1a with catalysts prepared from [Rh(COD)2]BF4 and 4a 
Entry P-OP ligand % conv % ee (conf) 
1 4b 69 80 (S) 
2 4e 38 76 (S) 
3 4f 80 60 (R) 
4 4g 33 63 (S) 
5 4h 20 75 (S) 
6 4i 82 8 (S) 
7 4j 70 75 (S) 
8 4k 41 81 (R) 
9 4l 90 93 (S) 
10 4m 70 77 (R) 
aReactions were carried out at room temperature with an initial hydrogen pressure of 20 bar unless 
otherwise specified. S/C = 100, reaction time 21 h. Conversion was determined by 1H NMR and 
enantiomeric excess by Chiral GC. 
 12
 
In addition, we were interested in examining the possibility to hydrogenate structurally related enol 
esters 2, as an appealing approach to the synthesis of chiral 2-hydroxytetralines. Unexpectedly, 
substrates 2 were very unreactive and no conversion was observed in reactions performed with catalyst 
precursor 5b under the reaction conditions used for enamides 1 (entries 12, 13). 
 
Table 3. Hydrogenation of substrates 1-3 with catalysts prepared from [Rh(COD)2]BF4 and 4a 
Entry P-OP ligand Substrate % conv % eeb 
1 4l 1b 40 93 (S) 
2 c 4l 1b 70 82 (S) 
3 4k 1b 24 50 (R) 
4 4l 1c 82 88 (S) 
5 4l 1d 80 86 (S) 
6 4a 1e 100 83 (S) 
7 4m 1e 100 81 (R) 
8 4l 1e 100 93 (S) 
9 4l 1f 67 83 (S) 
10c 4l 1f 70 81 (S) 
11 4m 1f 75 68 (R) 
12 4b 2a < 5 n. d. 
13 4b 2b < 5 n. d. 
14 4l 3 100 77 (R) 
15 4m 3 100 57 (S) 
aReactions were carried out at room temperature unless otherwise specified. S/C = 100, reaction time 21 
h. Conversion was determined by 1H NMR and enantiomeric excess by Chiral HPLC. bConfiguration for 
6d has been assigned by comparing optical rotation with literature data,4e while for the rest of 
compounds configuration has been assigned by analogy to that observed in hydrogenations of 1a and 1d. 
cReaction performed at 40 ºC. 
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For comparison, the performance of catalysts based on some ligands 4 in the hydrogenation of the 
enamide 3 has also been examined. Then, catalyst based on 4l provided full conversion giving the 
hydrogenated compound (R)-7 with a respectable 77 % ee (entry 14, Table 3). The diastereomeric 
catalyst precursor bearing ligand 4m provided the opposite enantiomer (S)-7 with a 57 % ee (entry 15). 
The configuration of the product is therefore determined by the configuration of the phosphite fragment, 
as observed in the hydrogenation of substrates 1. Moreover, the configurations of 7 and 6d indicate the 
same sense for addition of hydrogen to 3 and 1d, respectively (Figure 3). 
 
 
 
Figure 3. Comparison of product configuration in the hydrogenation of 3 and 1d. 
 
Further mechanistic considerations. The challenging nature of substrates 1 for Rh hydrogenation 
along with the lack of mechanistic information about this particular reaction in the literature, prompted 
us to investigate several fundamental features of these substrates connected with their hydrogenations. 
At this respect, a first aspect of interest regards the coordination mode of enamides 1 towards a [Rh(4)]+ 
fragment. For this purpose, representative enamide 1d was chosen. 
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A compound of composition [Rh(4c)(1d)]BF4 was prepared by hydrogenation of [Rh(COD)(4c)]BF4 
in DME, followed by evaporation of the solvent, dissolution in CD2Cl2 and addition of two equivalents 
of 1d (Figure 4). An analysis of the resulting mixture by 31P{1H} NMR showed the presence of two 
species in ca. 3:1 ratio characterized by rather similar spectral data. The major species appears as two 
doublet of doublets centered at 125.8 ppm (1JRhP = 322 Hz, 2JPP = 76 Hz) and 24.8 ppm (1JRhP = 187 
Hz), for the phosphine and phosphite fragments, respectively. The minor species likewise appears as two 
doublet of doublets centered at 127.5 ppm (1JRhP = 330 Hz, 2JPP = 76 Hz) and 23.6 ppm (1JRhP = 188 
Hz). In addition, an analysis of the major compound by a 2D COSY experiment, allowed us to identify 
the signals for Hc and Hd, while the 2D NOESY experiment showed contacts between Hb and Hc with 
the OMe group, as well as between Ha and Hb. From this information it can be concluded that Ha, Hb, Hc 
and Hd appeared at 6.76, 4.97, 5.84 (d, 3JHH = 7.0 Hz) and 4.12 (d) ppm, respectively, in the major 
compound (Table 4, entry 2). For comparison, it should be mentioned that Ha appeared in the free 
substrate at 7.09 ppm, while the aromatic protons Hb, Hc and Hd showed signals at 6.59, 6.58 (d, 3JHH = 
7.5 Hz) and 6.96 (d) ppm, respectively (entry 1). Therefore, there is an important high field displacement 
of the signals of aromatic protons upon coordination of 1d. These shifts are in good accord with a η6-
arene coordination mode.23 In addition, the relatively high values for 1JRhP are similar to values found 
before for other arene adducts of Rh compounds with phosphine-phosphite ligands.11c This coordination 
mode can be further confirmed by the chemical shifts of the corresponding Cb-Cd nuclei in the 13C{1H} 
NMR experiment, assigned with the help of a HMQC experiment. Therefore, CHb, CHc and CHd signals 
appeared for the major isomer at 85.0, 92.2 and 94.8 ppm, respectively (entry 2). For comparison, the 
corresponding signals appear in the free substrate at 111.2, 111.7 and 128.0 ppm, respectively (entry 1). 
Similar high field shifts were observed in the 1H NMR spectrum for the minor species, and Hb, Hc and 
Hd signals are centered at 5.93, 4.64 and 5.81 ppm, respectively (entry 3), also supporting a η6-arene 
coordination. From these data, it is reasonable to propose that the two compounds observed in solution 
are diastereomers resulting from coordination of 1d by each of its diastereotopic faces. Interestingly, no 
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exchange between adducts was observed in the 2D EXSY experiment pointed to a slow decoordination 
of the arene adduct in the NMR time-scale. 
 
Figure 4. Synthesis of arene complex [Rh(4c)(η6-1d)]BF4. 
 
Table 4. 1H and 13C{1H} NMR data of 1d and isomers of complex [Rh(4c)(η6-1d)]BF4¶ 
Entry Compound Ha Hb Hc Hd Ca Cb Cc Cd 
1 1d 7.09 6.58 6.59 6.96 110.8 111.2 111.7 128.0 
2 [Rh(4c)(1d)]+ 
(maj) 
6.76 4.97 5.84 4.12 102.9 85.5 91.8 94.9 
3§ [Rh(4c)(1d)]+ 
(min) 
6.39 5.92 5.81 4.65 104.6 91.8 n. a. n. a. 
¶All spectra registered in CD2Cl2 except 13C{1H} NMR of [Rh(1d)(4l)]BF4, recorded in CDCl3. See 
Figure 3 for notation. §Signals for Cc and Cd nuclei of the minor isomer were not detected in the HMQC 
experiment due to low concentration. 
 
It is remarkable to note that the η6-arene coordination mode exhibited by 1d is unusual for an N-acyl 
enamide, which typically shows a O,C,C chelating mode in Rh(I) complexes.7 On the contrary, arene 
complexes formed by the corresponding hydrogenated products, therefore lacking the olefin bond, are 
well known in the literature.24 
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The participation of complexes of formula [Rh(4)(η6-1)]+ in the catalytic reaction would however 
depend on the mechanism of the hydrogenation of 1. In a detailed study, Gridnev and Imamoto have 
compared the energy profile of several mechanistic pathways for the hydrogeanation of MAC with Rh 
catalysts bearing strong donor diphosphines,25 pointing to routes involving hydrogen addition prior to 
olefin coordination as the most favourable ones. In addition, the hydrogenations described herein are 
performed at moderate hydrogen pressures, while compound [Rh(4c)(η6-1d)]BF4 has been formed in the 
absence of hydrogen. However, considering that the stability of Rh(III) dihydrides is favored by electron 
rich ligands,26 the low donor ability of P-OP ligands may shift the preference for an unsaturated pathway 
(i. e. olefin coordination prior to hydrogen addition). At this respect, Maseras and Vidal have proposed 
an unsaturated mechanism for the hydrogenation of MAC with Rh catalysts bearing phosphine-
phosphite ligands.27 If an analogous pathway is followed in the present system, dissociation of the arene 
ring from the 18-electron [Rh(4)(η6-1)]+ and recoordination of 1 in a less stable [Rh(4)(O,C,C-1]+ 
(Figure 5) should occur to start the hydrogenation cycle. Moreover it should be recalled that Heller has 
nicely demonstrated the detrimental effect that the formation of stable η6-arene complexes produce on 
hydrogenation rate, due to the reduced available amount of rhodium complex for catalysis.23c Following 
this reasoning, the coordination mode exhibited by 1d would agree with the relatively low rates 
exhibited by substrates 1. As an illustrative comparison, it can be mentioned that hydrogenation of MAC 
or dimethyl itaconate with complexes 5 at S/C = 100 under 1 bar of hydrogen are typically finished after 
1-2 h, while under these reaction conditions conversion after 72 h for substrates 1a, 1c and 1d were 70, 
56 and 53 %, using catalyst bearing ligand 4l. Likewise, the lack of reactivity of enol-esters 2 can also be 
attributed to the formation of η6-arene species, as the inability of α-acyloxyacrylates to displace η6-
benzene has been reported before.28 
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Figure 5. Expected formation of the [Rh(4c)(O,C,C-1d]+ complex from [Rh(4c)(η6-1d)]+. 
 
In addition, we considered of fundamental interest to investigate the deuteration of selected substrates 
1c and 1d under our standard conditions (20 bar D2, S/C = 100, room temperature). An analysis of 
product 6d by 1H, 2H and 13C{1H} showed a single isotopomer in solution, in which labeling was 
observed in positions Ha1 and Hg (Figure 6), in good accord with the characteristic cis addition to the 
double bond. No deuterium incorporation was observed either in position 3 or in the aromatic ring. 
Likewise, compound 6c showed a similar pattern. An analysis of the enantioselectivity of these reactions 
indicated values of 89 and 87 % ee, for 6c and 6d, respectively, identical within the experimental error 
to those of the hydrogenation reactions (88 and 86 % ee, respectively). In this context it is pertinent to 
recall the enantioreversal observed in the hydrogenation of α- and β-acyloxyvinylphosphonates with 
complexes 5, which has been rationalized on the formation of α- and β-alkyl intermediates, 
respectively.11c Thus, a possible factor for erosion of enantioselectivity in the hydrogenation of 
substrates 1 could be a competition between α- and β-alkyl pathways, considering that they can provide 
opposite enantiomers.11 At this regard, a mechanistic study has connected the observation of an isotopic 
effect on enantioselectivity in Rh catalyzed enamide hydrogenation with the competition between α- and 
β-alkyl pathways.29 Based upon that line of reasoning, the absence of isotopic effect observed in the 
hydrogenation of 1c and 1d, would agree with an absence of competition between the two pathways. 
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Figure 6. 1H NMR spectrum of 6d (a); 1H NMR spectrum (b) and 2H NMR spectra (c) of product 
obtained by deuteration of 1d with [Rh(COD)(4b)]BF4. 
 
 
Conclusions 
 
The enantioselective catalytic hydrogenation of enamides 1 with rhodium catalysts based on modular 
phosphine-phosphite ligands 4 has been studied. A broad screening with these catalysts indicates that the 
hydrogenation of 1 is very sensitive to subtle changes in ligand backbone, pointing to the need of a 
precise optimization of the catalyst structure for substrates 1. Following this approach a highly 
enantioselective catalyst based on a ligand with an ethane backbone and a P-stereogenic phosphine 
fragment, with matched phosphine and biphenyl configurations, has been found. This catalyst provides 
high enantioselectivities, ranging from 83 to 93 % ee, in the hydrogenation of several –OMe and –Br 
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substituted substrates 1. In contrast, structurally related enol esters 2 show very little reactivity. 
Unexpectedly, the addition of DIPEA to the reaction has a dramatic effect increasing catalyst activity but 
leading to racemic products. 
Coordination studies of representative enamide 1d have shown a marked preference for a η6-arene 
coordination in a Rh(I) complex, which is in accord with the relatively low rates shown by these 
substrates. Moreover, deuteration of substrates 1c and 1d under the standard reaction conditions show a 
clean 1,2-cis addition to the double bond, without isotopic effect on enantioselectivity. The results 
obtained, however, did not show a distinctive feature of the hydrogenation of substrates 1, responsible of 
the rather difficult control of enantioselectivity in these reactions. 
 
 
Experimental Section 
 
General Procedures. All reactions and manipulations were performed under nitrogen or argon, either 
in a glovebox or using standard Schlenk-type techniques. All solvents were distilled under nitrogen with 
the following desiccants: sodium-benzophenone-ketyl for diethyl ether (Et2O) and tetrahydrofuran 
(THF); sodium for hexanes and toluene; CaH2 for dichloromethane (CH2Cl2); and NaOMe for methanol 
(MeOH). Phosphine-phosphite ligands 4 were prepared as described previously.14 Enamides 1,3 enol 
esters 216 and enamide 330 were synthesized according to literature procedures. All other reagents were 
purchased from commercial suppliers and used as received. 31P{1H} NMR shifts were referenced to 
external 85% H3PO4, while 13C{1H} and 1H shifts were referenced to the residual signals of deuterated 
solvents. All data are reported in ppm downfield from SiMe4. All NMR measurements were carried out 
at 25 °C, unless otherwise stated. HRMS data were obtained on a quadrupole analyzer. 
[Rh(COD)(4c)]BF4 (5c). Ligand 4c (0.100 g, 0.15 mmol) dissolved in CH2Cl2 (5 mL) was added 
dropwise to a solution of [Rh(COD)2]BF4 (0.056 g, 0.15 mmol) in CH2Cl2 (5 mL). The resulting orange 
solution was stirred for 1 h, concentrated up to one-fourth of its initial volume and filtered. Et2O (20 
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mL) was added to the above solution to precipitate the complex. The solid was filtered off, washed with 
Et2O (3 × 10 mL) and dried. Yellow solid (0.104 g, 69%). 1H NMR (500 MHz, CDCl3): δ = 7.66 (d,  J = 
11 Hz, 2H), 7.29 (s, 1H), 7.25 (s, 1H), 7.16 (s, 1H), 7.15 (s, 1H), 6.92 (d, J = 11 Hz, 2H), 5.86 (br s, 
1H), 5.17 (br s, 1H), 4.60 (m, 1H), 4.37 (br s, 2H), 3.98 (m, 2H), 3.01 (m, 1H), 2.47 (m, 3H), 2.42 (s, 
6H), 2.35 (s, 6H), 2.30 (s, 3H), 2.24 (s, 3H), 2.17 (m, 2H), 2.03 (m, 4H), 1.84 (s, 3H), 1.76 (s, 3H), 1.66 
(s, 9H), 1.38 (s, 9H); 31P{1H} NMR (202 MHz, CDCl3): δ = 118.7 (dd, JPRh = 246 Hz, JPP = 60 Hz, P-
O), 4.05 (dd, JPRh = 140 Hz, P-C); 13C{1H} NMR (101 MHz, CDCl3): δ = 144.7 (d, J = 6 Hz), 144.0 (d, 
J = 13 Hz), 139.7 (d, J = 11 Hz), 139.5 (d, J = 10 Hz), 137.0, 137.0, 136.3, 135.5, 134.9, 134.0, 133.5, 
133.0, 132.9, 129.8, 129.8, 129.3, 129.2, 129.1, 128.7, 128.6, 128.4, 128.2, 128.2, 110.5 (dd, J = 13 Hz, 
J = 6 Hz), 107.3 (dd, J = 12 Hz, J = 6 Hz), 106.2 (m), 94.8 (m), 64.9, 35.0, 35.0, 32.4, 31.8, 31.3, 30.7, 
30.3, 28.8, 26.0 (dd, J = 31 Hz, J = 13 Hz), 21.7, 21.6, 20.6, 20.5, 16.8, 16.6; elemental analysis calcd 
(%) for C50H66BF4O3P2Rh: C, 62.12; H, 6.88; found: C 61.92, H 7.15. 
General procedure for the synthesis of enamides 1. Enamides 1 were prepared by an adaptation of a 
literature procedure3 as described below. In a 250 mL round-bottom flask equipped with a Dean-Stark 
apparatus were introduced the ketone (10 mmol), the primary amide (25 mmol) and TsOH (1 mmol) in 
toluene (60 mL). The mixture was refluxed for 20 h under an inert atmosphere. After cooling down to 
room temperature, 150 mL of a saturated solution of sodium hydrogen carbonate were added and the 
mixture was warmed to 60 ºC for 30 min. After cooling down to room temperature, the organic layer 
was extracted, washed with water (3 x 100 mL), dried over magnesium sulfate and concentrated. The 
enamide was purified by chromatography on silica gel or isolated by crystallization. 
N-(6-methoxy-3,4-dihydronaphthalen-2-yl)-acetamide (1c). Obtained following the general 
procedure as a white powder (0.61 g, 50% yield) after flash column chromatography on silica gel 
(AcOEt/hexane, 6/1): mp: 124-127º; 1H NMR (500 MHz, CDCl3): δ = 7.01 (s, 1H), 6.96 (d, J = 7.8 Hz, 
1H), 6.65 (m, 3H), 3.78 (s, 3H), 2.86 (t, J = 7.5 Hz, 2H),
 
2.43 (t, J = 7.5 Hz, 2H), 2.10 (s, 3H); 13C{1H} 
NMR (126 MHz, CDCl3): δ = 168.4, 158.1, 134.5, 132.8, 127.7, 127.1, 113.7, 111.4, 111.3, 55.4, 28.5, 
27.5, 24.8; HRMS (EI): m/z 217.1102, [M]+ (exact mass calcd for C13H15NO2: 217.1103). 
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N-(8-methoxy-3,4-dihydronaphthalen-2-yl)-acetamide (1e). Obtained as a white powder by 
crystallization in a CH2Cl2/n-hexane (1:1) mixture (0.6 g, 50% yield): mp: 168-171º; 1H NMR (500 
MHz, CDCl3): δ = 7.17 (s, 1H), 7.03 (t, J = 7.8 Hz, 1H), 6.70 (d, J = 7.8 Hz, 2H), 6.65 (br s, 1H), 3.81 
(s, 3H), 2.86 (t, J = 8.0 Hz, 2H), 2.52 (t, J = 8.0 Hz, 2H), 2.10 (s, 3H); 13C{1H} NMR (126 MHz, 
CDCl3): δ= 168.2, 154.7, 135.0, 134.4, 126.4, 123.4, 119.8, 108.9, 105.7, 55.6, 28.4, 26.9, 24.8; HRMS 
(EI): m/z 217.1110, [M]+ (exact mass calcd for C13H15NO2: 217.1103). 
N-(6-Br-3,4-dihydronaphthalen-2-yl)-acetamide (1f). Prepared according to the general procedure 
and purified by crystallization in toluene. White crystalline solid (0.34 g, 30% yield): mp: 196-199º; 1H 
RMN (500 MHz, CDCl3): δ = 7.24 (d, J = 8.0 Hz, 1H), 7.19 (s, 1H), 7.07 (s, 1H), 6.89 (d, J = 8.0 Hz, 
1H), 6.58 (br s, 1H), 2.85 (t, J = 8.1 Hz, 2H), 2.41 (t, J = 8.1 Hz, 2H), 2.12 (s, 3H); 13C{1H} NMR (126 
MHz, CDCl3): δ = 168.5, 135.3, 134.7, 133.8, 130.0, 129.8, 127.6, , 110.5, 27.8, 27.5, 24.9; HRMS (EI): 
m/z 265.0103, [M]+ (exact mass calcd for C12H12NOBr: 265.0102). 
General Procedure for Catalytic Hydrogenation Reactions. In a glovebox, the appropriate olefin 
(0.036 mmol), phosphine-phosphite ligand (0.46 µmol) and [Rh(COD)2]BF4 (0.42 µmol) from freshly 
prepared stock solutions in CH2Cl2 (total volume = 0.5 mL), were added to a 2 mL glass vial. Vials were 
placed in a steel reaction vessel model HEL CAT18 that holds up to eighteen reactions. The reactor was 
purged three times with H2 and finally pressurized to the required pressure. In the case of deuteration 
reactions the reactor was purged with Ar, partially evacuated under vacuum and filled with D2 at 20 atm. 
After the desired reaction time, the reactor was slowly depressurized, solutions were evaporated and 
conversions were determined by 1H NMR. The resulting mixtures were dissolved in EtOAc, and filtered 
through a short pad of silica to remove the catalyst. Enantiomeric excess was analyzed by chiral GC or 
HPLC, as follows: N-(1,2,3,4-tetrahydronaphthalen-2-yl)-acetamide (6a): GC, Supelco β-DEX 110; 
100 °C (2 min), then 2 °C/min up to 190 °C; 28.0 psi He; t1 = 46.41 min, t2 = 46.59 min; N-(1,2,3,4-
tetrahydronaphthalen-2-yl)-benzamide (6b): HPLC, Daicel Chiralcel OJ-H 90:10/ n-hexane:i-PrOH, 
t1 = 18.5 min., t2= 22.3 min; N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-acetamide (6c): 
HPLC, Daicel Chiralcel OJ-H 90:10/ n-hexane:i-PrOH, t1 = 20.82 min., t2= 30.70 min.; N-(7-methoxy-
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1,2,3,4-tetrahydronaphthalen-2-yl)-acetamide (6d): HPLC, Daicel Chiralcel OJ-H 90:10/ n-hexane:i-
PrOH, t1 = 20.6 min., t2= 32.9 min; N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-acetamide 
(6e): HPLC, Daicel Chiralcel OJ-H 90:10/ n-hexane:i-PrOH, t1 = 12.12 min., t2= 13.54 min.; N-(6-Br-
1,2,3,4-dihydronaphthalen-2-yl)-acetamide (6f): HPLC, Daicel Chiralcel OJ-H 90:10/ n-hexane:i-
PrOH, t1 = 11.09 min., t2= 13.18 min.; N-(1,2,3,4-tetrahydronaphthalen-1-yl)-acetamide (7): HPLC, 
Daicel Chiralcel OJ-H 99.5:0.5/ n-hexane:i-PrOH, t1 = 14.6 min., t2= 15.6 min. 
N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-acetamide (6c). Obtained with a 82 % 
conversion following the general procedure, further purified by preparative TLC (CH2Cl2/n-hexane: 9:1) 
giving 6c as a yellow solid (26 % yield): mp: 109-112º; [α]D 20 = -25.1 (c 0.1, CHCl3, S enantiomer 88 % 
ee); 1H NMR (500 MHz, CDCl3) δ = 6.97 (d, J = 8.4 Hz, 1H), 6.70 (dd, J = 2.4 Hz, J = 8.4 Hz, 1H), 
6.64 (d, J = 2.5 Hz, 1H), 5.51 (br s, 1H), 4.28 (m, 1H), 3.78 (s, 3H), 3.05 (dd, J = 4.9 Hz, J = 15.9 Hz, 
1H), 2.85 (m, 2H; CH2), 2.57 (dd, J = 7.7 Hz, J = 16.0 Hz, 1H), 2.03 (m, 1H), 1.98 (s, 3H), 1.79 (m, 
1H); 13C{1H} NMR (100.6 MHz, CDCl3): δ = 169.9, 158.1, 136.7), 130.5, 126.0, 113.5, 112.5, 55.4, 
45.5, 35.0, 28.5, 27.3, 23.7; HRMS (EI): m/z 219.1256, [M]+ (exact mass calcd for C13H17NO2: 
219.1259). 
N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-acetamide (6e). According to the general 
procedure, obtained with a 95 % yield. Yellow powder: mp: 119-122º; [α]D 20 = -27.0 (c 0.1,CHCl3, S 
enantiomer 93 % ee); 1H NMR (400 MHz, CDCl3): δ = 7.12 (t, J = 8.0 Hz, 1H), 6.73 (d, J = 8.0 Hz, 
1H), 6.67 (d, J = 8.0 Hz, 1H), 5.65 (br s, 1H), 4.27 (m, 1H), 3.80 (s, 3H), 3.06 (dd, J = 6.0 Hz, J = 17.3 
Hz, 1H), 2.85 (m, 2H), 
 
2.45 (dd, J = 8.0 Hz, J = 17.3 Hz 1H), 2.04 (m, 1H), 2.10 (s, 3H), 1.76 (m, 1H); 
13C{1H} NMR (126 MHz, CDCl3): δ = 170.0, 157.6, 137.0, 126.6, 123.1, 121.1, 107.2, 55.4, 45.3, 29.8, 
28.3, 27.3, 23.6; HRMS (EI): m/z 219.1258, [M]+ (exact mass calcd for C13H17NO2: 219.1259). 
N-(6-Br-1,2,3,4-dihydronaphthalen-2-yl)-acetamide (6f). According to the general procedure 
compound 6f was obtained with a 70 % conversion. Attempts to separate it from remaining 3f were 
unsuccessful, therefore 6f is assessed by NMR and HRMS: 1H NMR (500 MHz, CDCl3): δ = 7.23 (m, 
2H), 6.93 (d, J = 8.0 Hz, 1H), 5.48 (br s, 1H), 4.27 (m, 1H), 3.07 (dd, J = 4.8 Hz, J = 16.5 Hz, 1H),
 
2.85 
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(m, 2H; CH2), 2.57 (dd, J = 8.1 Hz, J = 16.5 Hz, 1H), 2.04 (m, 1H), 1.99 (s, 3H), 1.73 (m, 1H); 13C{1H} 
NMR (126 MHz, CDCl3): δ = 169.7, 162.6, 137.9, 133.1, 131.7, 131.2, 129.2, 45.0, 35.4, 29.9, 28.4, 
27.0, 23.7; HRMS (CI): m/z 268.0347, [M+H]+ (exact mass calcd for C12H15BrNO: 268.0337). 
[Rh(4c)(1d)]BF4. Compound 5c (18 mg, 0.02 mmol) was dissolved in DME (0.5 mL) and the solution 
pressurized with 4 bars of hydrogen. The reaction was monitored until dissapearance of the starting 
material and the resulting solution evaporated to dryness. The resulting residue was dissolved in CD2Cl2 
and 1d (9 mg, 0.04 mmol) was added. The resulting solution showed the enamide adduct as a mixture of 
two isomers (maj and min) in a ca. 3:1 ratio. Assignment of aromatic protons of coordinated 1d (see 
next figure) have been made with the help of NOESY, COSY and HMQC experiments: 1H NMR (500 
MHz, CD2Cl2): δ = 7.82 (s, 1H), 7.38 (s, 1H), 7.27 (d, J = 10.5 Hz, 2H), 7.26 (s, 1H), 7.17 (s, 2H), 7.02 
(d, J = 12.0 Hz, 2H), 6.76 (s, 1H, Ha), 5.85 (dd, J = 7.0 Hz, J = 2.0 Hz, 1H, Hc), 4.97 (s, 1H, Hb), 4.34 
(m, 2H), 4.10 ((d, J = 7.0 Hz, 1H, Hd), 4.03 (m, 2H), 3.09 (s, 3H), 2.60 (m, 2H), 2.41 (s, 3H), 2.36 (s, 
6H), 2.33 (s, 6H), 2.26 (m, 2H), 2.25 (s, 3H), 2.12 (s, 3H), 2.07 (s, 3H), 2.01 (s, 3H), 1.52 (s, 9H), 1.45 
(s, 9H); 31P{1H} NMR (CD2Cl2, 162 MHz): δ = 136.4 (dd, JRhP = 345 Hz, JPP = 69 Hz, PO), 26.4 (dd, 
JRhP = 191 Hz, JPP = 69 Hz, PC); 13C{1H} NMR (125.8 MHz, CDCl3): δ = 170.2, 145.9, 142.3, 139.3, 
139.1, 139.0, 137.2, 136.3, 136.2, 135.6, 134.1, 134.0, 133.8, 133.1, 132.8, 132.2, 131.9, 131.8, 130.1, 
130.0, 129.6, 129.5, 128.7, 127.9, 110.6, 102.5 (CHa), 94.4 (CHd), 91.0 (CHc), 84.5 (CHb), 63.9, 55.8, 
33.0, 32.9, 32.1, 31.8, 26.8, 25.1, 24.6, 21.5, 21.4, 21.3, 20.5, 20.2, 16.7, 16.3. Characteristic signals for 
the min isomer: 1H NMR (500 MHz, CD2Cl2): δ = 6.25 (s, 1H, H arom, Hb), 5.84 (d, J = 7.0 Hz, 1H, H 
arom, Hc), 4.43 (s, 1H, H arom, Hd), 3.58 (s, 3H, C(O)Me); 31P{1H} NMR (CD2Cl2, 162 MHz): δ = 
139.3 (dd, JRhP = 354 Hz, JPP = 74 Hz, PO), 27.7 (dd, JRhP = 191 Hz, JPP = 74 Hz, PC); 13C{1H} NMR 
(126 MHz, CDCl3): δ = 90.6 (CHc), 91.0 (CHb), 56.3 (OMe). Due to low intensity CHc and CHd signals 
for the min isomer could not be located. MS (ESI): m/z 988.4, [M]+ (mass calcd for C55H69NO5P2Rh: 
988.4). 
 24
H
NO
O
ab
c
d
 
ACKNOWLEDGMENT. We thank Prof. Ilya Gridnev (Tohoku University) for helpful comments. 
MICINN (CTQ2009-11867 and CONSOLIDER-INGENIO, CSD2007-00006, FEDER support) and 
Junta de Andalucía (2008/ FQM-3830 and 2009/FQM-4832) are also acknowledged for financial 
support. P. K. acknowledges EU for an early stage researcher contract (PITN 2008-215193). We also 
thank CITIUS for technical support on NMR and HRMS experiments. 
 
Supporting Information Available.  
NMR spectra for compounds 1, 6, [Rh(COD)(4c)]BF4 and [Rh(4c)(1d)]BF4. This material is available 
free of charge via the Internet at http://pubs.acs.org. 
 25
 
References 
 
1. (a) Tschaen, D. M.; Abramson, L.; Cai, D.; Desmond, R.; Dolling, U.-H.; Frey, L.; Karady, S.; Shi, 
Y.-J.; Verhoeven, T. R. J. Org. Chem. 1995, 60, 4324. (b) Vermeulen, E. S.; Schmidt, A. W.; Sprouse, 
J. S.; Wikström, H. V.; Grol, C. J. J. Med. Chem. 2003, 46, 5365. (c) Holmberg, P.; Sohn, D.; 
Leideborg, R.; Caldirola, P.; Zlatoidsky, P.; Hanson, S.; Mohell, N.; Rosqvist, S.; Nordvall, G.; 
Johansson, A. M.; Johansson, R. J. Med. Chem. 2004, 47, 3927. (d) Beliaev, A.; Learmonth, D. A.; 
Soares-da-Silva, P. J. Med. Chem. 2006, 49, 1191. (e) Imanishi, M.; Nakajima, Y.; Tomishima, Y.; 
Hamashima, H.; Washizuka, K.; Sakurai, M.; Matsui, S.; Imamura, E.; Ueshima, K.; Yamamoto, T.; 
Yamamoto, N.; Ishikawa, H.; Nakano, K.; Unami, N.; Hamada, K.; Matsumura, Y.; Takamura, F.; 
Hattori, K. J. Med. Chem. 2008, 51, 4804. (f) Roy, K. K.; Saxena, A. K. J. Chem. Inf. Mod. 2011, 51, 
1405. 
2. For some examples of pharmaceutical products based on chiral 2-aminotetralines see following 
references. Nepicastat: Stanley, W. C.; Li, B.; Bonhaus, D. W.; Johnson, L. G.; Lee, K.; Porter, S.; 
Walker, K.; Martinez, G.; Eglen, R. M.; Whiting, R. L.; Hegde, S. S. Brit. J. Pharm. 1997, 121, 1803. 
SR58611A: Hu, B.; Jennings, L. L. Prog. Med. Chem. 2003, 41, 167. AR-A2: Federsel, H.-J.; Hedberg, 
M.; Qvarnström, F. R.; Sjögren, M. P. T.; Tian, W. Acc. Chem. Res. 2007, 40, 1377. Rotigotine: Chen, 
J. J.; Swope, D. M.; Dashtipour, K.; Lyons, K. E. Pharmacotherapy 2009, 29, 1452. LY274600: 
Foreman, M. M.; Fuller, R. W.; Leander, J. D.; Nelson, D. L.; Calligaro, D. O.; Lucaites, V. L.; Wong, 
D. T.; Zhang, L.; Barrett, J. E.; Schaus, J. M. Drug Dev. Res. 1995, 34, 66. Terutroban: Osende, J. I.; 
Shimbo, D.; Fuster, V.; Dubar, M.; Badimon, J. J. J. Thromb. Haemost. 2004, 2, 492. 
3. (a) Dupau, P.; Bruneau, C.; Dixneuf, P. H. Tetrahedron: Asymm. 1999, 10, 3467. (b) Dupau, P.; 
Bruneau, C.; Dixneuf, P. H. Tetrahedron: Asymm. 1999, 10, 3471. 
 
 26
4. (a) Devocelle, M.; Mortreux, A.; Agbossou, F.; Dormoy, J.-R. Tetrahedron Lett. 1999, 40, 4551. (b) 
Dupau, P.; Bruneau, C.; Dixneuf, P. H. Adv. Synth. Catal. 2001, 343, 331. (c) Renaud, J. L.; Dupau, P.; 
Hay, A. E.; Guingouain, M.; Dixneuf, P. H.; Bruneau, C. Adv. Synth. Catal. 2003, 345, 230. (d) 
Imanishi, M.; Nakajima, Y.; Tomishima, Y.; Hamashima, H.; Washizuka, K.; Sakurai, M.; Matsui, S.; 
Imamura, E.; Ueshima, K.; Yamamoto, T.; Yamamoto, N.; Ishikawa, H.; Nakano, K.; Unami, N.; 
Hamada, K.; Matsumura, Y.; Takamura, F.; Hattori, K. J. Med. Chem. 2008, 51, 4804. (e) Pautigny, C.; 
Debouit, C.; Vayron, P.; Ayad, T.; Ratovelomanana-Vidal, V. Tetrahedron: Asymm. 2010, 21, 1382. 
5. (a) Zhang, Z.; Zhu, G.; Jiang, Q.; Xiao, D.; Zhang, X. J. Org. Chem. 1999, 64, 1774. (b) Argouarch, 
G.; Samuel, O.; Kagan, H. B. Eur. J. Org. Chem. 2000, 2885. (c) Tang, W.; Chi, Y.; Zhang, X. Org. 
Lett. 2002, 4, 1695. (d) Hoen, R.; van den Berg, M.; Bernsmann, H.; Minnaard, A. J.; de Vries, J. G.; 
Feringa, B. L. Org. Lett. 2004, 6, 1433. (e) Bernsmann, H.; van den Berg, M.; Hoen, R.; Minnaard, A. 
J.; Mehler, G.; Reetz, M. T.; De Vries, J. G.; Feringa, B. L. J. Org. Chem. 2005, 70, 943. (f) Patureau, F. 
W.; de Boer, S.; Kuil, M.; Meeuwissen, J.; Breuil, P.-A. R.; Siegler, M. A.; Spek, A. L.; Sandee, A. J.; 
de Bruin, B.; Reek, J. N. H. J. Am. Chem. Soc. 2009, 131, 6683. (g) Meeuwissen, J.; Kuil, M.; van der 
Burg, A. M.; Sandee, A. J.; Reek, J. N. H. Chem. Eur. J. 2009, 15, 10272. (h) Breuil, P.-A. R.; Reek, J. 
N. H. Eur. J. Org. Chem. 2009, 2009, 6225. (i) Revés, M.; Ferrer, C.; León, T.; Doran, S.; Etayo, P.; 
Vidal-Ferran, A.; Riera, A.; Verdaguer, X. Angew. Chem. Int. Ed. 2010, 49, 9452. (j) Revés, M.; Ferrer, 
C.; León, T.; Doran, S.; Etayo, P.; Vidal-Ferran, A.; Riera, A.; Verdaguer, X. Angew. Chem. Int. Ed. 
2011, 50, 8776. (k) Pignataro, L.; Boghi, M.; Civera, M.; Carboni, S.; Piarulli, U.; Gennari, C. Chem. 
Eur. J. 2012, 18, 1383. 
6. Patureau, F. W.; Worch, C.; Siegler, M. A.; Spek, A. L.; Bolm, C.; Reek, J. N. H. Adv. Synth. Catal. 
2012, 354, 59. 
7. (a) Chan, A. S. C.; Pluth, J. J.; Halpern, J. J. Am. Chem. Soc. 1980, 102, 5952. (b) Drexler, H.-J.; 
Baumann, W.; Schmidt, T.; Zhang, S.; Sun, A.; Spannenberg, A.; Fischer, C.; Buschmann, H.; Heller, 
D. Angew. Chem. Int. Ed. 2005, 44, 1184. (c) Schmidt, T.; Dai, Z.; Drexler, H.-J.; Baumann, W.; Jäger, 
C.; Pfeifer, D.; Heller, D. Chem. Eur. J. 2008, 14, 4469. 
 27
8. Jiang, X.-B.; Lefort, L.; Goudriaan, P. E.; de Vries, A. H. M.; van Leeuwen, P. W. N. M.; de Vries, J. 
G.; Reek, J. N. H. Angew. Chem. Int. Ed. 2006, 45, 1223. 
9. (a) Tang, W.; Zhang, X. Chem. Rev. 2003, 103, 3029. (b) Xie, J.-H.; Zhu, S.-F.; Zhou, Q.-L. Chem. 
Rev. 2010, 111, 1713. 
10. (a) Feldgus, S.; Landis, C. R. Organometallics 2001, 20, 2374. (b) Donoghue, P. J.; Helquist, P.; 
Wiest, O. J. Org. Chem. 2007, 72, 839. 
11. (a) Gridnev, I. D.; Higashi, N.; Imamoto, T. J. Am. Chem. Soc. 2000, 122, 10486. (b)  
Yasutake, M.; Gridnev, I. D.; Higashi, N.; Imamoto, T. Org. Lett. 2001, 3, 1701. (c) Chávez, M. Á.; 
Vargas, S.; Suárez, A.; Álvarez, E.; Pizzano, A. Adv. Synth. Catal. 2011, 353, 2775. 
12. Chen, J.; Zhang, W.; Geng, H.; Li, W.; Hou, G.; Lei, A.; Zhang, X. Angew. Chem. Int. Ed. 2009, 48, 
800. 
13. (a) Vineyard, B. D.; Knowles, W. S.; Sabacky, M. J.; Bachman, G. L.; Weinkauff, D. J. J. Am. 
Chem. Soc. 1977, 99, 5946. (b) Koenig, K. E.; Knowles, W. S. J. Am. Chem. Soc. 1978, 100, 7561. (c) 
Miyashita, A.; Takaya, H.; Souchi, T.; Noyori, R. Tetrahedron 1984, 40, 1245. 
14. (a) Suarez, A.; Mendez-Rojas, M. A.; Pizzano, A. Organometallics 2002, 21, 4611. (b) Rubio, M.; 
Vargas, S.; Suarez, A.; Alvarez, E.; Pizzano, A. Chem. Eur. J. 2007, 13, 1821. (c) Vargas, S.; Suarez, 
A.; Alvarez, E.; Pizzano, A. Chem. Eur. J. 2008, 14, 9856. (d) Arribas, I.; Vargas, S.; Rubio, M.; 
Suarez, A.; Domene, C.; Alvarez, E.; Pizzano, A. Organometallics 2010, 29, 5791. 
15. For some studies on the biological activitiy of hydroxytetraline derivatives, see for instance: (a) 
Dourish, C. T.; Hutson, P. H.; Curzon, G. Brain Res. Bull. 1985, 15, 377. (b) Seiler, M. P.; Stoll, A. P.; 
Closse, A.; Frick, W.; Jaton, A.; Vigouret, J. M. J. Med. Chem. 1986, 29, 912. (c) Lévesque, D.; Diaz, 
J.; Pilon, C.; Martres, M. P.; Giros, B.; Souil, E.; Schott, D.; Morgat, J. L.; Schwartz, J. C.; Sokoloff, P. 
Proc. Nat Ac. Sci. 1992, 89, 8155. (d) Lejeune, F.; Newman-Tancredi, A.; Audinot, V.; Millan, M. J. J. 
Pharmacol. Exp. Ther. 1997, 280, 1241. (e) Assié, M.-B.; Koek, W. Brit. J. Pharm. 2000, 130, 1348. 
 28
16. Li, B.-J.; Xu, L.; Wu, Z.-H.; Guan, B.-T.; Sun, C.-L.; Wang, B.-Q.; Shi, Z.-J. J. Am. Chem. Soc. 
2009, 131, 14656. 
17. However, at the optimal Rh/P of ca. 3, this catalyst also gives a high enantioselectivity (91 % ee) in 
the absence of amine. 
18. The different response to the addition of DIPEA between  the Supraphos catalyst and those based on 
phosphine-phosphites 4 may look surprising. However, either the size or the expected flexibility of the 
backbone in the Supraphos catalyst, which may even allow a trans coordination of the bidentate ligand,19 
or even the third equivalent of phosphorus ligand, are remarkable differences between the two catalytic 
systems which can be responsible for the different influence of base on them. 
19. For a highly enantioselective system based on a trans ligand that operates in the presence of base, 
see: Kuwano, R.; Sato, K.; Kurokawa, T.; Karube, D.; Ito, Y. J. Am. Chem. Soc. 2000, 122, 7614. 
20. (a) Schrock, R. R.; Osborn, J. A. J. Am. Chem. Soc. 1976, 98, 2134. (b) Schrock, R. R.; Osborn, J. 
A. J. Am. Chem. Soc. 1976, 98, 4450. (c) Raebiger, J. W.; DuBois, D. L. Organometallics 2004, 24, 
110. 
21. Preetz, A.; Baumann, W.; Drexler, H.-J.; Fischer, C.; Sun, J.; Spannenberg, A.; Zimmer, O.; Hell, 
W.; Heller, D. Chem. As. J. 2008, 3, 1979. 
22. (a) MacNeil, P. A.; Roberts, N. K.; Bosnich, B. J. Am. Chem. Soc. 1981, 103, 2273. (b) Bakos, J.; 
Tóth, I.; Heil, B.; Szalontai, G.; Párkányi, L.; Fülöp, V. J. Organomet. Chem. 1989, 370, 263. 
23. (a) Singewald, E. T.; Slone, C. S.; Stern, C. L.; Mirkin, C. A.; Yap, G. P. A.; Liable-Sands, L. M.; 
Rheingold, A. L. J. Am. Chem. Soc. 1997, 119, 3048. (b) Heller, D.; Drexler, H.-J.; Spannenberg, A.; 
Heller, B.; You, J.; Baumann, W. Angew. Chem. Int. Ed. 2002, 41, 777. (c) Fischer, C.; Thede, R.; 
Drexler, H.-J.; König, A.; Baumann, W.; Heller, D. Chem. Eur. J. 2012, 18, 11920. 
24. (a) Gridnev, I. D.; Imamoto, T.; Hoge, G.; Kouchi, M.; Takahashi, H. J. Am. Chem. Soc. 2008, 130, 
2560. (b) Gridnev, I. D.; Alberico, E.; Gladiali, S. Chem. Commun. 2012, 48, 2186. 
 29
25. Imamoto, T.; Tamura, K.; Zhang, Z.; Horiuchi, Y.; Sugiya, M.; Yoshida, K.; Yanagisawa, A.; 
Gridnev, I. D. J. Am. Chem. Soc. 2011, 134, 1754. 
26. Gridnev, I. D.; Higashi, N.; Imamoto, T. Organometallics 2001, 20, 4542. 
27. Fernández-Pérez, H.; Donald, S. M. A.; Munslow, I. J.; Benet-Buchholz, J.; Maseras, F.; Vidal-
Ferran, A. Chem. Eur. J. 2010, 16, 6495. 
28. Burk, M. J.; Kalberg, C. S.; Pizzano, A. J. Am. Chem. Soc. 1998, 120, 4345. 
29. Imamoto, T.; Itoh, T.; Yoshida, K.; Gridnev, I. D. Chem.As. J. 2008, 3, 1636. 
30. Van den Berg, M.; Haak, R. M.; Minnaard, A. J.; de Vries, A. H. M.; de Vries, J. G.; Feringa, B. L. 
Adv. Synth. Catal. 2002, 344, 1003. 
 
